yahoo_financeOriginal article
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
Phase 2positiveLAM-001Positive
AI Analysis
Summary
Quince Therapeutics reported positive Phase 2a data for LAM-001, an inhaled therapy candidate. The announcement marks progress in the company's clinical development program.
Clinical Trial Data
Phase
2a
Importance:6/10
Sentiment:
0.70
Phase 2clinical trialinhaled therapypositive data
Related Companies
Read the original article
Published by yahoo_finance on June 2, 2026 1:56 PM